source
- AbbVie licenses Nxera's EP4 gut-targeting IBD program for up to $1.47 billionAbbVie announced a licensing agreement with Nxera Pharma to acquire rights to its EP4 receptor agonist program aimed at inflammatory bowel disease. The deal includes an upfront payment of $100 mil…
- Novo projects flat 2026 sales as CFO exits, marking an upgrade from prior expectationsNovo announced that its 2026 sales outlook will be flat, a shift from earlier growth expectations. The drugmaker also disclosed that its chief financial officer will be leaving the company, and a…